GRCL - Gracell Biotechnologies to Participate in Oppenheimer 32nd Annual Healthcare Conference

PALO ALTO, Calif. and SUZHOU, China, March 10, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in the Oppenheimer 32 ^nd Annual Healthcare Conference from March 15 ^th to 17 ^th .

The Gracell team is scheduled to have a presentation at 11:20am – 11:50am Eastern Time, Tuesday, March 15 ^th and will host virtual investor meetings at the conference on March 15 ^th .

A webcast of the presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit ir.gracellbio.com .

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR, TruUCAR and SMART CART™ technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com . Follow @GracellBio on LinkedIn .

Media contact
Marvin Tang
marvin.tang@gracellbio.com

Investor contact
Gracie Tong
gracie.tong@gracellbio.com